AstraZeneca PLC (AZN)
NASDAQ: AZN · IEX Real-Time Price · USD
78.71
+0.65 (0.83%)
At close: Jul 19, 2024, 4:00 PM
79.58
+0.87 (1.11%)
Pre-market: Jul 22, 2024, 6:40 AM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $47.61B in the twelve months ending March 31, 2024, with 8.60% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $12.68B with 16.55% year-over-year growth. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
$47.61B
Revenue Growth
+8.60%
P/S Ratio
5.13
Revenue / Employee
$529,600
Employees
89,900
Market Cap
244.04B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
Dec 31, 2005 | 23.95B | 2.52B | 11.78% |
Dec 31, 2004 | 21.43B | 2.58B | 13.67% |
Dec 31, 2003 | 18.85B | 1.01B | 5.65% |
Dec 31, 2002 | 17.84B | - | - |
Dec 31, 2001 | - | - | - |
Dec 31, 2000 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Novo Nordisk | 35.35B |
AZN News
- 3 days ago - These Stocks Offer Gains Without the U.S. Political Drama - Barrons
- 7 days ago - AstraZeneca Closes Acquisition of Amolyt Pharma - GlobeNewsWire
- 21 days ago - AstraZeneca's COVID prevention drug application gets EU fast-track assessment - Reuters
- 24 days ago - German vaccine panel endorses Astra-Sanofi's RSV shot for infants - Reuters
- 25 days ago - Tanium Plays Critical Role in Supporting AstraZeneca's Mission to Deliver Life-Changing Medicines - Business Wire
- 26 days ago - China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment - Reuters
- 27 days ago - AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer - Reuters
- 4 weeks ago - AstraZeneca's breast cancer drug combination fails in late-stage trial - Reuters